1
|
Lopez S, Hallali N, Lalatonne Y, Hillion A, Antunes JC, Serhan N, Clerc P, Fourmy D, Motte L, Carrey J, Gigoux V. Magneto-mechanical destruction of cancer-associated fibroblasts using ultra-small iron oxide nanoparticles and low frequency rotating magnetic fields. Nanoscale Adv 2022; 4:421-436. [PMID: 36132704 PMCID: PMC9417452 DOI: 10.1039/d1na00474c] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 11/18/2021] [Indexed: 05/15/2023]
Abstract
The destruction of cells using the mechanical activation of magnetic nanoparticles with low-frequency magnetic fields constitutes a recent and interesting approach in cancer therapy. Here, we showed that superparamagnetic iron oxide nanoparticles as small as 6 nm were able to induce the death of pancreatic cancer-associated fibroblasts, chosen as a model. An exhaustive screening of the amplitude, frequency, and type (alternating vs. rotating) of magnetic field demonstrated that the best efficacy was obtained for a rotating low-amplitude low-frequency magnetic field (1 Hz and 40 mT), reaching a 34% ratio in cell death induction; interestingly, the cell death was not maximized for the largest amplitudes of the magnetic field. State-of-the-art kinetic Monte-Carlo simulations able to calculate the torque undergone by assemblies of magnetic nanoparticles explained these features and were in agreement with cell death experiments. Simulations showed that the force generated by the nanoparticles once internalized inside the lysosome was around 3 pN, which is in principle not large enough to induce direct membrane disruption. Other biological mechanisms were explored to explain cell death: the mechanical activation of magnetic nanoparticles induced lysosome membrane permeabilization and the release of the lysosome content and cell death was mediated through a lysosomal pathway depending on cathepsin-B activity. Finally, we showed that repeated rotating magnetic field exposure halted drastically the cell proliferation. This study established a proof-of-concept that ultra-small nanoparticles can disrupt the tumor microenvironment through mechanical forces generated by mechanical activation of magnetic nanoparticles upon low-frequency rotating magnetic field exposure, opening new opportunities for cancer therapy.
Collapse
Affiliation(s)
- Sara Lopez
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
- INSERM ERL1226, Receptology and Targeted Therapy of Cancers 1 Avenue du Professeur Jean Poulhes F-31432 Toulouse France
| | - Nicolas Hallali
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
| | - Yoann Lalatonne
- Université Sorbonne Paris Nord, Laboratory for Vascular Translational Science, LVTS, INSERM, UMR 1148 F-93000 Bobigny France
- Services de Biochimie et Médecine Nucléaire, Hôpital Avicenne Assistance Publique-Hôpitaux de Paris F-93009 Bobigny France
| | - Arnaud Hillion
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
| | - Joana C Antunes
- Université Sorbonne Paris Nord, Laboratory for Vascular Translational Science, LVTS, INSERM, UMR 1148 F-93000 Bobigny France
| | - Nizar Serhan
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
- INSERM ERL1226, Receptology and Targeted Therapy of Cancers 1 Avenue du Professeur Jean Poulhes F-31432 Toulouse France
| | - Pascal Clerc
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
- INSERM ERL1226, Receptology and Targeted Therapy of Cancers 1 Avenue du Professeur Jean Poulhes F-31432 Toulouse France
| | - Daniel Fourmy
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
- INSERM ERL1226, Receptology and Targeted Therapy of Cancers 1 Avenue du Professeur Jean Poulhes F-31432 Toulouse France
| | - Laurence Motte
- Université Sorbonne Paris Nord, Laboratory for Vascular Translational Science, LVTS, INSERM, UMR 1148 F-93000 Bobigny France
| | - Julian Carrey
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
| | - Véronique Gigoux
- Laboratoire de Physique et Chimie des Nano-Objets (LPCNO), CNRS-UPS-INSA UMR5215 135 Avenue de Rangueil F-31077 Toulouse France
- INSERM ERL1226, Receptology and Targeted Therapy of Cancers 1 Avenue du Professeur Jean Poulhes F-31432 Toulouse France
| |
Collapse
|
2
|
Mouchel PL, Serhan N, Betous R, Farge T, Saland E, De Medina P, Hoffmann JS, Sarry JE, Poirot M, Silvente-Poirot S, Récher C. Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. Cancers (Basel) 2020; 12:cancers12102933. [PMID: 33053669 PMCID: PMC7601603 DOI: 10.3390/cancers12102933] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 10/02/2020] [Accepted: 10/08/2020] [Indexed: 12/28/2022] Open
Abstract
Simple Summary Recently, several molecules have improved the clinical outcome of acute myeloid leukemia (AML) patients. Despite these recent advances, their prognosis remains poor and new strategies to improve the standard anthracycline and Ara-C-based chemotherapy are needed. We recently published that dendrogenin A (DDA), a mammalian cholesterol metabolite with tumor-suppressor properties, can potentiate the effect of Ara-C to kill AML cells. In this study, we find that DDA can also potentiate anthracycline against AML. The potentiation of Ara-C by DDA is due to a switch from a protective autophagy to a deadly autophagy. Regarding anthracyclines, the potentiation of daunorubicin is caused by the modulation of the efflux by the PgP pump, and that of idarubicin, to an increase in DNA damage and to the induction of a rapid and lethal autophagy. This is caused by rapid modulation of AKT/mTOR and JNK activity, two major pathways involved both in DNA repair and lethal autophagy. Abstract Dendrogenin A (DDA), a mammalian cholesterol metabolite with tumor suppressor properties, has recently been shown to exhibit strong anti-leukemic activity in acute myeloid leukemia (AML) cells by triggering lethal autophagy. Here, we demonstrated that DDA synergistically enhanced the toxicity of anthracyclines in AML cells but not in normal hematopoietic cells. Combination index of DDA treatment with either daunorubicin or idarubicin indicated a strong synergism in KG1a, KG1 and MV4-11 cell lines. This was confirmed in vivo using immunodeficient mice engrafted with MOLM-14 cells as well as in a panel of 20 genetically diverse AML patient samples. This effect was dependent on Liver X Receptor β, a major target of DDA. Furthermore, DDA plus idarubicin strongly increased p53BP1 expression and the number of DNA strand breaks in alkaline comet assays as compared to idarubicin alone, whereas DDA alone was non-genotoxic. Mechanistically, DDA induced JNK phosphorylation and the inhibition of AKT phosphorylation, thereby maximizing DNA damage induced by idarubicin and decreasing DNA repair. This activated autophagic cell death machinery in AML cells. Overall, this study shows that the combination of DDA and idarubicin is highly promising and supports clinical trials of dendrogenin A in AML patients.
Collapse
Affiliation(s)
- Pierre-Luc Mouchel
- Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, 31059 Toulouse, France;
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
| | - Nizar Serhan
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
- Team “Cholesterol Metabolism and Therapeutic Innovations”, Cancer Research Center of Toulouse (CRCT), UMR 1037, Inserm-Université de Toulouse 3, Equipe labellisée par la ligue contre le cancer, 31037 Toulouse, France;
| | - Rémy Betous
- CRCT, Université de Toulouse, Inserm, CNRS, UPS, 31000 Toulouse, France;
- Equipe Labellisée Ligue Contre le Cancer, Laboratoire d’Excellence Toulouse Cancer, 31037 Toulouse, France
| | - Thomas Farge
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
| | - Estelle Saland
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
| | | | - Jean-Sébastien Hoffmann
- Laboratoire d’Excellence Toulouse Cancer (TOUCAN), Laboratoire de pathologie, Institut Universitaire du Cancer-Toulouse, Oncopole, 31037 Toulouse, France;
| | - Jean-Emmanuel Sarry
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
| | - Marc Poirot
- Team “Cholesterol Metabolism and Therapeutic Innovations”, Cancer Research Center of Toulouse (CRCT), UMR 1037, Inserm-Université de Toulouse 3, Equipe labellisée par la ligue contre le cancer, 31037 Toulouse, France;
- Correspondence: (M.P.); (C.R.)
| | - Sandrine Silvente-Poirot
- Team “Cholesterol Metabolism and Therapeutic Innovations”, Cancer Research Center of Toulouse (CRCT), UMR 1037, Inserm-Université de Toulouse 3, Equipe labellisée par la ligue contre le cancer, 31037 Toulouse, France;
| | - Christian Récher
- Service d’Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, 31059 Toulouse, France;
- Centre de Recherches en Cancérologie de Toulouse, UMR1037, Inserm, Université de Toulouse 3 Paul Sabatier, Equipe Labellisée LIGUE 2018, F-31037 Toulouse, France; (N.S.); (T.F.); (E.S.); (J.-E.S.)
- Correspondence: (M.P.); (C.R.)
| |
Collapse
|
3
|
Serhan N, Mouchel PL, de Medina P, Segala G, Mougel A, Saland E, Rives A, Lamaziere A, Despres G, Sarry JE, Larrue C, Vergez F, Largeaud L, Record M, Récher C, Silvente-Poirot S, Poirot M. Dendrogenin A synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers (Basel) 2020; 12:cancers12071725. [PMID: 32610562 PMCID: PMC7407291 DOI: 10.3390/cancers12071725] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Revised: 06/19/2020] [Accepted: 06/25/2020] [Indexed: 12/20/2022] Open
Abstract
Dendrogenin A (DDA) is a mammalian cholesterol metabolite that displays potent antitumor properties on acute myeloid leukemia (AML). DDA triggers lethal autophagy in cancer cells through a biased activation of the oxysterol receptor LXRβ, and the inhibition of a sterol isomerase. We hypothesize that DDA could potentiate the activity of an anticancer drug acting through a different molecular mechanism, and conducted in vitro and in vivo combination tests on AML cell lines and patient primary tumors. We report here results from tests combining DDA with antimetabolite cytarabine (Ara-C), one of the main drugs used for AML treatment worldwide. We demonstrated that DDA potentiated and sensitized AML cells, including primary patient samples, to Ara-C in vitro and in vivo. Mechanistic studies revealed that this sensitization was LXRβ-dependent and was due to the activation of lethal autophagy. This study demonstrates a positive in vitro and in vivo interaction between DDA and Ara-C, and supports the clinical evaluation of DDA in combination with Ara-C for the treatment of AML.
Collapse
Affiliation(s)
- Nizar Serhan
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
| | - Pierre-Luc Mouchel
- Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France; (P.-L.M.); (E.S.); (J.-E.S.); (C.L.)
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Université de Toulouse, 31400 Toulouse, France; (F.V.); (L.L.)
| | - Philippe de Medina
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
| | - Gregory Segala
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
| | - Aurélie Mougel
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
| | - Estelle Saland
- Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France; (P.-L.M.); (E.S.); (J.-E.S.); (C.L.)
| | - Arnaud Rives
- AFFICHEM, 31400 Toulouse, France;
- Dendrogenix, 4000 Liège, Belgium
| | - Antonin Lamaziere
- Laboratory of Mass Spectrometry, Institut National de la Santé et de la Recherche Médicale (INSERM) ERL 1157, Centre national de la recherche scientifique (CNRS) Unité Mixte de Recherche (UMR) 7203 LBM, Sorbonne Universités-UPMC, CHU Saint-Antoine, 75012 Paris, France; (A.L.); (G.D.)
| | - Gaëtan Despres
- Laboratory of Mass Spectrometry, Institut National de la Santé et de la Recherche Médicale (INSERM) ERL 1157, Centre national de la recherche scientifique (CNRS) Unité Mixte de Recherche (UMR) 7203 LBM, Sorbonne Universités-UPMC, CHU Saint-Antoine, 75012 Paris, France; (A.L.); (G.D.)
| | - Jean-Emmanuel Sarry
- Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France; (P.-L.M.); (E.S.); (J.-E.S.); (C.L.)
| | - Clément Larrue
- Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France; (P.-L.M.); (E.S.); (J.-E.S.); (C.L.)
| | - François Vergez
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Université de Toulouse, 31400 Toulouse, France; (F.V.); (L.L.)
| | - Laetitia Largeaud
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Université de Toulouse, 31400 Toulouse, France; (F.V.); (L.L.)
| | - Michel Record
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
| | - Christian Récher
- Cancer Research Center of Toulouse (CRCT), Unité Mixte de Recherche (UMR) 1037 Inserm/Université Toulouse III-Paul Sabatier, ERL5294 Centre national de la recherche scientifique (CNRS), Team Drug Resistance and Oncometabolism in Acute Myeloid Leukemia, 31037 Toulouse, France; (P.-L.M.); (E.S.); (J.-E.S.); (C.L.)
- Service d’Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU de Toulouse, Université de Toulouse, 31400 Toulouse, France; (F.V.); (L.L.)
- Correspondence: (C.R.); (S.S.-P.); (M.P.); Tel.: +33-5-31-15-63-55 (C.R.); +33-5-82-74-16-28 (S.S.-P.); +33-5-82-74-16-26 (M.P.)
| | - Sandrine Silvente-Poirot
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
- Correspondence: (C.R.); (S.S.-P.); (M.P.); Tel.: +33-5-31-15-63-55 (C.R.); +33-5-82-74-16-28 (S.S.-P.); +33-5-82-74-16-26 (M.P.)
| | - Marc Poirot
- Unité Mixte de Recherche (UMR) 1037, Cancer Research Center of Toulouse (CRCT), Institut National de la Santé et de la Recherche Médicale (INSERM) Université de Toulouse, Team Cholesterol Metabolism and Therapeutic Innovations, Equipe labellisée par la Ligue Contre le Cancer, 31037 Toulouse, France; (N.S.); (P.d.M.); (G.S.); (A.M.); (M.R.)
- Correspondence: (C.R.); (S.S.-P.); (M.P.); Tel.: +33-5-31-15-63-55 (C.R.); +33-5-82-74-16-28 (S.S.-P.); +33-5-82-74-16-26 (M.P.)
| |
Collapse
|
4
|
El Hajj Diab D, Clerc P, Serhan N, Fourmy D, Gigoux V. Combined Treatments of Magnetic Intra-Lysosomal Hyperthermia with Doxorubicin Promotes Synergistic Anti-Tumoral Activity. Nanomaterials (Basel) 2018; 8:E468. [PMID: 29954075 PMCID: PMC6071107 DOI: 10.3390/nano8070468] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 06/14/2018] [Accepted: 06/19/2018] [Indexed: 11/25/2022]
Abstract
Doxorubicin is a cytotoxic drug used for the treatment of many cancer types. However, its significant dose-related adverse effects including cardiotoxicity may hamper its efficiency. Moreover, the multidrug resistance that appears during treatments limits anti-cancer therapies. Hyperthermia has been introduced as an adjuvant anti-cancer therapy and presents promising opportunities especially in combination with chemotherapy. However, hyperthermia methods including standard magnetic hyperthermia do not discriminate between the target and the surrounding normal tissues and can lead to side effects. In this context, a Magnetic Intra-Lysosomal Hyperthermia (MILH) approach, which occurs without perceptible temperature rise, has been developed. We previously showed that minute amounts of iron oxide magnetic nanoparticles targeting the gastrin receptor (CCK2R) are internalized by cancer cells through a CCK2R-dependent physiological process, accumulated into their lysosomes and kill cancer cells upon high frequency alternating magnetic field (AMF) application through lysosomal cell death. Here, we show that the combination of MILH with doxorubicin increases the efficiency of the eradication of endocrine tumor cells with synergism. We also demonstrate that these two treatments activate two different cell death pathways that are respectively dependent on Caspase-1 and Caspase-3 activation. These findings will result in the development of new anti-tumoral, intra-lysosomal-thermo/chemotherapy with better curative effects than chemotherapy alone and that are devoid of adverse effects linked to standard hyperthermia approaches.
Collapse
Affiliation(s)
- Darine El Hajj Diab
- INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, France.
| | - Pascal Clerc
- INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, France.
| | - Nizar Serhan
- INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, France.
| | - Daniel Fourmy
- INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, France.
| | - Véronique Gigoux
- INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F-31432 Toulouse, France.
| |
Collapse
|
5
|
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discov 2017; 7:716-735. [PMID: 28416471 PMCID: PMC5501738 DOI: 10.1158/2159-8290.cd-16-0441] [Citation(s) in RCA: 512] [Impact Index Per Article: 73.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Revised: 06/15/2016] [Accepted: 04/12/2017] [Indexed: 12/12/2022]
Abstract
Chemotherapy-resistant human acute myeloid leukemia (AML) cells are thought to be enriched in quiescent immature leukemic stem cells (LSC). To validate this hypothesis in vivo, we developed a clinically relevant chemotherapeutic approach treating patient-derived xenografts (PDX) with cytarabine (AraC). AraC residual AML cells are enriched in neither immature, quiescent cells nor LSCs. Strikingly, AraC-resistant preexisting and persisting cells displayed high levels of reactive oxygen species, showed increased mitochondrial mass, and retained active polarized mitochondria, consistent with a high oxidative phosphorylation (OXPHOS) status. AraC residual cells exhibited increased fatty-acid oxidation, upregulated CD36 expression, and a high OXPHOS gene signature predictive for treatment response in PDX and patients with AML. High OXPHOS but not low OXPHOS human AML cell lines were chemoresistant in vivo. Targeting mitochondrial protein synthesis, electron transfer, or fatty-acid oxidation induced an energetic shift toward low OXPHOS and markedly enhanced antileukemic effects of AraC. Together, this study demonstrates that essential mitochondrial functions contribute to AraC resistance in AML and are a robust hallmark of AraC sensitivity and a promising therapeutic avenue to treat AML residual disease.Significance: AraC-resistant AML cells exhibit metabolic features and gene signatures consistent with a high OXPHOS status. In these cells, targeting mitochondrial metabolism through the CD36-FAO-OXPHOS axis induces an energetic shift toward low OXPHOS and strongly enhanced antileukemic effects of AraC, offering a promising avenue to design new therapeutic strategies and fight AraC resistance in AML. Cancer Discov; 7(7); 716-35. ©2017 AACR.See related commentary by Schimmer, p. 670This article is highlighted in the In This Issue feature, p. 653.
Collapse
Affiliation(s)
- Thomas Farge
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| | - Estelle Saland
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| | - Fabienne de Toni
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| | - Nesrine Aroua
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| | - Mohsen Hosseini
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Robin Perry
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Claudie Bosc
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Mayumi Sugita
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Lucille Stuani
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Marine Fraisse
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Sarah Scotland
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Clément Larrue
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Héléna Boutzen
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Virginie Féliu
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Sorbonne Universités, UPMC Université Paris 06, UMR-S 938, CDR Saint-Antoine, Paris, France
| | - Marie-Laure Nicolau-Travers
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | | | - Nicolas Broin
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Marion David
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Nizar Serhan
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
| | - Audrey Sarry
- Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
| | - Suzanne Tavitian
- Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - Tony Kaoma
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg
| | - Laurent Vallar
- Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Strassen, Luxembourg
| | - Jason Iacovoni
- Inserm, Institut des Maladies Métaboliques et Cardiovasculaires, U1048, Toulouse, France
| | - Laetitia K Linares
- Inserm, Institut de Recherche en Cancérologie de Montpellier, U1194, Montpellier, France
- Université de Montpellier, Montpellier, France
- Institut Régional du Cancer Montpellier, Montpellier, France
| | - Camille Montersino
- Inserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
- Université Aix-Marseille, Marseille, France
- CNRS, UMR7258, Marseille, France
| | - Rémy Castellano
- Inserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
- Université Aix-Marseille, Marseille, France
- CNRS, UMR7258, Marseille, France
| | | | - Yves Collette
- Inserm, Centre de Recherche en Cancérologie de Marseille, U1068, Marseille, France
- Institut Paoli-Calmettes, Marseille, France
- Université Aix-Marseille, Marseille, France
- CNRS, UMR7258, Marseille, France
| | - Olivier Duchamp
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
- Oncodesign, Dijon, France
| | - Yara Barreira
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
- Inserm, Service d'Expérimentation Animale, UMS006, Toulouse, France
| | - Pierre Hirsch
- Sorbonne Universités, UPMC Université Paris 06, UMR-S 938, CDR Saint-Antoine, Paris, France
- Inserm, UMR-S938, CDR Saint-Antoine, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, GRC n°07, Groupe de Recherche Clinique sur les Myéloproliférations Aiguës et Chroniques MyPAC, Paris, France
- AP-HP, Hôpital Saint-Antoine, Paris, France
| | - Tony Palama
- Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques & des Procédés, Toulouse, France
- CNRS, UMR5504, Toulouse, France
| | - Lara Gales
- Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques & des Procédés, Toulouse, France
- CNRS, UMR5504, Toulouse, France
| | - François Delhommeau
- Sorbonne Universités, UPMC Université Paris 06, UMR-S 938, CDR Saint-Antoine, Paris, France
- Inserm, UMR-S938, CDR Saint-Antoine, Paris, France
- Sorbonne Universités, UPMC Université Paris 06, GRC n°07, Groupe de Recherche Clinique sur les Myéloproliférations Aiguës et Chroniques MyPAC, Paris, France
- AP-HP, Hôpital Saint-Antoine, Paris, France
| | - Barbara H Garmy-Susini
- Inserm, Institut des Maladies Métaboliques et Cardiovasculaires, U1048, Toulouse, France
| | - Jean-Charles Portais
- Université de Toulouse III Paul Sabatier, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques & des Procédés, Toulouse, France
- CNRS, UMR5504, Toulouse, France
| | - François Vergez
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| | - Mary Selak
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Gwenn Danet-Desnoyers
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Martin Carroll
- Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Christian Récher
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
- Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - Jean-Emmanuel Sarry
- Inserm, Cancer Research Center of Toulouse, U1037, Toulouse, France.
- Université de Toulouse, Toulouse, France
- Consortium IMODI "Innovative MODels Initiative against Cancer," France
| |
Collapse
|
6
|
Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations. Mol Cancer Ther 2015. [PMID: 26206337 DOI: 10.1158/1535-7163.mct-15-0163] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We assessed the antileukemic activity of 2-deoxy-d-glucose (2-DG) through the modulation of expression of receptor tyrosine kinases (RTK) commonly mutated in acute myeloid leukemia (AML). We used human leukemic cell lines cells, both in vitro and in vivo, as well as leukemic samples from AML patients to demonstrate the role of 2-DG in tumor cell growth inhibition. 2-DG, through N-linked glycosylation inhibition, affected the cell-surface expression and cellular signaling of both FTL3-ITD and mutated c-KIT and induced apoptotic cell death. Leukemic cells harboring these mutated RTKs (MV4-11, MOLM-14, Kasumi-1, and TF-1 c-KIT D816V) were the most sensitive to 2-DG treatment in vitro as compared with nonmutated cells. 2-DG activity was also demonstrated in leukemic cells harboring FLT3-TKD mutations resistant to the tyrosine kinase inhibitor (TKI) quizartinib. Moreover, the antileukemic activity of 2-DG was particularly marked in c-KIT-mutated cell lines and cell samples from core binding factor-AML patients. In these cells, 2-DG inhibited the cell-surface expression of c-KIT, abrogated STAT3 and MAPK-ERK pathways, and strongly downregulated the expression of the receptor resulting in a strong in vivo effect in NOD/SCID mice xenografted with Kasumi-1 cells. Finally, we showed that 2-DG decreases Mcl-1 protein expression in AML cells and induces sensitization to both the BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w, ABT-737, and cytarabine. In conclusion, 2-DG displays a significant antileukemic activity in AML with FLT3-ITD or KIT mutations, opening a new therapeutic window in a subset of AML with mutated RTKs.
Collapse
Affiliation(s)
- Clément Larrue
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France
| | - Estelle Saland
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France
| | - François Vergez
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France. Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Nizar Serhan
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France
| | - Eric Delabesse
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France. Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Véronique Mansat-De Mas
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France. Laboratoire d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Marie-Anne Hospital
- Institut Cochin, Département Développement, Reproduction, Cancer, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 8104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016, Paris, France. Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
| | - Jérôme Tamburini
- Institut Cochin, Département Développement, Reproduction, Cancer, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 8104, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016, Paris, France. Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France
| | - Stéphane Manenti
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France
| | - Jean Emmanuel Sarry
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France
| | - Christian Récher
- Cancer Research Center of Toulouse (CRCT), UMR1037 INSERM, ERL5294 CNRS, Toulouse, France. Université Toulouse III Paul Sabatier, Toulouse, France. Service d'Hématologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
| |
Collapse
|
7
|
Lichtenstein L, Serhan N, Espinosa-Delgado S, Fabre A, Annema W, Tietge UJF, Robaye B, Boeynaems JM, Laffargue M, Perret B, Martinez LO. Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport. Cardiovasc Res 2015; 106:314-23. [PMID: 25770145 DOI: 10.1093/cvr/cvv109] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Accepted: 03/07/2015] [Indexed: 11/14/2022] Open
Abstract
AIMS High-density lipoproteins (HDLs) protect against atherosclerosis mainly due to their function in hepatobiliary reverse cholesterol transport (RCT). This is a process whereby excess cholesterol from peripheral tissues is transported by HDL particles to the liver for further metabolism and biliary excretion. Hepatic uptake of HDL holoparticles involves the P2Y13 receptor, independently of the selective cholesteryl ester uptake mediated by scavenger receptor class B, type I (SR-BI). Accordingly, P2Y13-deficient mice (P2Y13 (-/-)) have impaired RCT. This study assessed whether P2Y13 deficiency would affect atherosclerotic development. METHODS AND RESULTS P2Y13 (-/-) mice were crossbred with atherosclerosis-prone apoE(-/-) mice. When 15 weeks old, P2Y13 (-/-)/apoE(-/-) mice had more aortic sinus lesions than apoE(-/-) mice. Bone marrow transplantation showed that the absence of the P2Y13 receptor in blood cells did not lead to significantly greater atherosclerotic plaque size formation compared with control apoE(-/-) reconstituted animals. Conversely, the absence of the P2Y13 receptor, except in blood cells, resulted in lesion sizes similar to that in P2Y13 (-/-)/apoE(-/-) reconstituted mice, pointing to a role for non-haematopoietic-derived P2Y13. Unexpectedly, P2Y13 (-/-)/apoE(-/-) mice displayed a lower HDL-cholesterol level than apoE(-/-) mice, which might be due to greater SR-BI expression in the liver. However, P2Y13 deficiency in apoE(-/-) mice was translated into reduced biliary and faecal sterol excretion and impaired RCT from macrophage to faeces, suggesting that an alteration in hepatobiliary RCT could be solely responsible for the greater atherosclerosis observed. CONCLUSION The P2Y13 receptor protects against atherosclerosis, primarily through its role in hepatobiliary RCT.
Collapse
Affiliation(s)
- Laeticia Lichtenstein
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Nizar Serhan
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Sara Espinosa-Delgado
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Aurélie Fabre
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Wijtske Annema
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Uwe J F Tietge
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Muriel Laffargue
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France
| | - Bertrand Perret
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - Laurent O Martinez
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, France Université de Toulouse III, UMR 1048, Toulouse, France CHU de Toulouse, Hôpital Purpan, Toulouse, France INSERM U1048, Bât. L3, Hôpital Rangueil, BP 84225, 31432 Toulouse cedex 04, France
| |
Collapse
|
8
|
Pons V, Serhan N, Gayral S, Malaval C, Nauze M, Malet N, Laffargue M, Galés C, Martinez LO. Role of the ubiquitin-proteasome system in the regulation of P2Y13 receptor expression: impact on hepatic HDL uptake. Cell Mol Life Sci 2014; 71:1775-88. [PMID: 24030815 PMCID: PMC11113673 DOI: 10.1007/s00018-013-1471-5] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 08/28/2013] [Accepted: 08/30/2013] [Indexed: 01/03/2023]
Abstract
The protective effect of high density lipoproteins (HDL) against atherosclerosis is mainly attributed to their capacity to transport excess cholesterol from peripheral tissues back to the liver for further elimination into the bile, a process called reverse cholesterol transport (RCT). Recently, the importance of the P2Y13 receptor (P2Y13-R) was highlighted in HDL metabolism since HDL uptake by the liver was decreased in P2Y13-R deficient mice, which translated into impaired RCT. Here, we investigated for the first time the molecular mechanisms regulating cell surface expression of P2Y13-R. When transiently expressed, P2Y13-R was mainly detected in the endoplasmic reticulum (ER) and strongly subjected to proteasome degradation while its homologous P2Y12 receptor (P2Y12-R) was efficiently targeted to the plasma membrane. We observed an inverse correlation between cell surface expression and ubiquitination level of P2Y13-R in the ER, suggesting a close link between ubiquitination of P2Y13-R and its efficient targeting to the plasma membrane. The C-terminus tail exchange between P2Y13-R and P2Y12-R strongly restored plasma membrane expression of P2Y13-R, suggesting the involvement of the intra-cytoplasmic tail of P2Y13-R in expression defect. Accordingly, proteasomal inhibition increased plasma membrane expression of functionally active P2Y13-R in hepatocytes, and consequently stimulated P2Y13-R-mediated HDL endocytosis. Importantly, proteasomal inhibition strongly potentiated HDL hepatic uptake (>200 %) in wild-type but not in P2Y13-R-deficient mice, thus reinforcing the role of P2Y13-R expression in regulating HDL metabolism. Therefore, specific inhibition of the ubiquitin-proteasome system might be a novel powerful HDL therapy to enhance P2Y13-R expression and consequently promote the overall RCT.
Collapse
Affiliation(s)
- Véronique Pons
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, 31432, France,
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Lichtenstein L, Serhan N, Annema W, Combes G, Robaye B, Boeynaems JM, Perret B, Tietge UJF, Laffargue M, Martinez LO. Lack of P2Y13 in mice fed a high cholesterol diet results in decreased hepatic cholesterol content, biliary lipid secretion and reverse cholesterol transport. Nutr Metab (Lond) 2013; 10:67. [PMID: 24476490 PMCID: PMC4029266 DOI: 10.1186/1743-7075-10-67] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 10/30/2013] [Indexed: 01/11/2023] Open
Abstract
Background The protective effect of HDL is mostly attributed to their metabolic function in reverse cholesterol transport (RCT), a process whereby excess cellular cholesterol is taken up from peripheral cells, processed in HDL particles, and later delivered to the liver for further metabolism and biliary secretion. Mechanistically, the purinergic P2Y13 ADP-receptor is involved in hepatic HDL endocytosis (i.e., uptake of both HDL protein + lipid moieties), which is considered an important step of RCT. Accordingly, chow-fed P2Y13 knockout (P2Y13-/-) mice exhibit lower hepatic HDL uptake, which translates into a decrease of hepatic free cholesterol content and biliary cholesterol and phospholipid secretion. Findings The aim of this study was to determine the effect of high cholesterol diet (HCD) in P2Y13-/- mice, in order to mimic high dietary cholesterol intake, which is a major cause of dyslipidemia in humans. As previously reported with chow-diet, HCD did not affect plasma lipid levels in P2Y13-/- compared with control mice but decreased hepatic free and esterified cholesterol content (p < 0.05, P2Y13-/- versus control). Interestingly, biliary lipid secretion and macrophages-to-feces RCT were more dramatically impaired in P2Y13-/- mice fed a HCD than chow-diet. HCD did not enhance atherosclerosis in P2Y13-/- compared with control mice. Conclusion This study demonstrates that high dietary cholesterol intake accentuated the metabolic phenotype of P2Y13-/- mice, with impaired hepatobiliary RCT. Although other animal models might be required to further evaluate the role of P2Y13 receptor in atherosclerosis, P2Y13 appears a promising target for therapeutic intervention aiming to stimulate RCT, particularly in individuals with lipid-rich diet.
Collapse
Affiliation(s)
- Laeticia Lichtenstein
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Nizar Serhan
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Wijtske Annema
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Guillaume Combes
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Bernard Robaye
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Jean-Marie Boeynaems
- Institute of Interdisciplinary Research, IRIBHM, Université Libre de Bruxelles, Gosselies, Belgium
| | - Bertrand Perret
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - Uwe J F Tietge
- Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
| | - Muriel Laffargue
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France
| | - Laurent O Martinez
- INSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse 31432, France.,Université de Toulouse III, UMR 1048, Toulouse 31300, France.,CHU de Toulouse, Hôpital Purpan, Toulouse, France
| |
Collapse
|
10
|
Beauvieux MC, Stephant A, Gin H, Serhan N, Couzigou P, Gallis JL. Resveratrol mainly stimulates the glycolytic ATP synthesis flux and not the mitochondrial one: a saturation transfer NMR study in perfused and isolated rat liver. Pharmacol Res 2013; 78:11-7. [PMID: 24090928 DOI: 10.1016/j.phrs.2013.09.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/12/2013] [Revised: 09/08/2013] [Accepted: 09/15/2013] [Indexed: 12/19/2022]
Abstract
Our aim was to monitor the effects of resveratrol (RSV) on the respective contribution of glycolysis and oxidative phosphorylation on the unidirectional flux of ATP synthesis in whole isolated rat liver perfused with Krebs-Henseleit Buffer (KHB). The rate of tissular ATP supply was measured directly by monitoring the chemical exchange Pi toward ATP with saturation transfer (ST) (31)P nuclear magnetic resonance, a method applied for the first time for studying the effects of RSV. ST allows the measurement of the total cellular Pi→ATP chemical exchange; after specific inhibition of glycolysis with iodacetate, ST could provide the Pi→ATP flux issued from mitochondria. This latter was compared to mitochondrial ATP turn-over evaluated after chemical ischemia (CI), performed with specific inhibition (KCN) of oxidative phosphorylation, and measured by standard (31)P NMR spectroscopy. In controls (KHB alone), the apparent time constant (ks) of Pi exchange toward ATP as measured by ST was 0.48±0.04s(-1) leading to a total ATP synthesis rate of 37±3.9μmolmin(-1)g(-1). KHB+RSV perfusion increased ks (+52%; p=0.0009 vs. KHB) leading to an enhanced rate of total ATP synthesis (+52%; p=0.01 vs. KHB). When glycolysis was previously inhibited in KHB, both ks and ATP synthesis flux dramatically decreased (-87% and -86%, respectively, p<0.0001 vs. KHB without inhibition), evidencing a collapse of Pi-to-ATP exchange. However, glycolysis inhibition in KHB+RSV reduced to less extent ks (-41%, p=0.0005 vs. KHB+RSV without inhibition) and ATP synthesis flux (-18%). Using the CI method in KHB and KHB+RSV, KCN addition after glycolysis inhibition induced a rapid fall to zero of the ATP content. The mitochondrial ATP turnover R(t0) and its time constant kd mito were similar in KHB (1.18±0.19μmolmin(-1)g(-1) and 0.91±0.13min(-1)) and KHB+RSV (1.36±0.26μmolmin(-1)g(-1) and 0.77±0.18min(-1)). Since mitochondrial ATP turnover was not increased by RSV, the stimulation of Pi-to-ATP exchange by RSV mainly reflected an increase in glycolytic ATP synthesis flux. Moreover, the maintenance by RSV of a high level of Pi-to-ATP exchange after glycolysis inhibition evidenced a protective effect of the polyphenol, in agreement with our previous hypothesis of a stimulation of substrate flux throughout the glycolysis 3-carbon step.
Collapse
Affiliation(s)
- Marie-Christine Beauvieux
- Centre de Résonance Magnétique des Systèmes Biologiques, UMR 5536 CNRS-Université, Bordeaux Segalen, LabEx TRAIL-IBIO, 146 rue Léo Saignat, F-33076 Bordeaux Cedex, France.
| | | | | | | | | | | |
Collapse
|
11
|
Serhan N, Cabou C, Verdier C, Lichtenstein L, Malet N, Perret B, Laffargue M, Martinez LO. Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion. Biochim Biophys Acta Mol Cell Biol Lipids 2012; 1831:719-25. [PMID: 23266391 DOI: 10.1016/j.bbalip.2012.12.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2012] [Revised: 12/10/2012] [Accepted: 12/12/2012] [Indexed: 11/16/2022]
Abstract
High level of high-density lipoprotein cholesterol (HDL-cholesterol) is inversely correlated to the risk of atherosclerotic cardiovascular disease. The protective effect of HDL is mostly attributed to their metabolic functions in reverse cholesterol transport (RCT), a process whereby excess cell cholesterol is taken up from peripheral cells and processed in HDL particles, and is later delivered to the liver for further metabolism and bile excretion. We have previously demonstrated that P2Y13 receptor is critical for RCT and that intravenous bolus injection of cangrelor (AR-C69931MX), a partial agonist of P2Y13 receptor, can stimulate hepatic HDL uptake and subsequent lipid biliary secretion without any change in plasma lipid levels. In the present study, we investigated the effect of longer-term treatment with cangrelor on lipoprotein metabolism in mice. We observed that continuous delivery of cangrelor at a rate of 35μg/day/kg body weight for 3days markedly decreased plasma HDL-cholesterol level, by increasing the clearance of HDL particles by the liver. These effects were correlated to an increase in the rate of biliary bile acid secretion. An increased expression of SREBP-regulated genes of cholesterol metabolism was also observed without any change of hepatic lipid levels as compared to non-treated mice. Thus, 3-day cangrelor treatment markedly increases the flux of HDL-cholesterol from the plasma to the liver for bile acid secretion. Taken together our results suggest that P2Y13 appears a promising target for therapeutic intervention aimed at preventing or reducing cardiovascular risk.
Collapse
Affiliation(s)
- Nizar Serhan
- INSERM, UMR 1048, Institut de Maladies Métaboliques et Cardiovasculaires, Toulouse, 31000, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T, Briand F, Collet X, Nijstad N, Tietge UJF, Robaye B, Perret B, Boeynaems JM, Martinez LO. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010; 52:1477-83. [PMID: 20830789 DOI: 10.1002/hep.23897] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
UNLABELLED A major atheroprotective functionality of high-density lipoproteins (HDLs) is to promote "reverse cholesterol transport" (RCT). In this process, HDLs mediate the efflux and transport of cholesterol from peripheral cells and its subsequent transport to the liver for further metabolism and biliary excretion. We have previously demonstrated in cultured hepatocytes that P2Y(13) (purinergic receptor P2Y, G protein-coupled, 13) activation is essential for HDL uptake but the potential of P2Y(13) as a target to promote RCT has not been documented. Here, we show that P2Y(13)-deficient mice exhibited a decrease in hepatic HDL cholesterol uptake, hepatic cholesterol content, and biliary cholesterol output, although their plasma HDL and other lipid levels were normal. These changes translated into a substantial decrease in the rate of macrophage-to-feces RCT. Therefore, hallmark features of RCT are impaired in P2Y(13)-deficient mice. Furthermore, cangrelor, a partial agonist of P2Y(13), stimulated hepatic HDL uptake and biliary lipid secretions in normal mice and in mice with a targeted deletion of scavenger receptor class B type I (SR-BI) in liver (hypomSR-BI-knockout(liver)) but had no effect in P2Y(13) knockout mice, which indicate that P2Y(13)-mediated HDL uptake pathway is independent of SR-BI-mediated HDL selective cholesteryl ester uptake. CONCLUSION These results establish P2Y(13) as an attractive novel target for modulating RCT and support the emerging view that steady-state plasma HDL levels do not necessarily reflect the capacity of HDL to promote RCT.
Collapse
Affiliation(s)
- Aurélie C Fabre
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 563, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|